EGFR and non-small cell lung carcinoma: Its efficacy was evaluated in a clinical phase III study (AURA3) that compared osimertinib with platinum‐based chemotherapy in EGFR T790M mutation‐positive patients with advanced NSCLC who had shown progressive disease (PD) after previous EGFR‐TKI treatment [4].